started · updated
U.S. Department of Health to fund ibogaine research for veteran PTSD
The U.S. Department of Health and Human Services will provide up to $4.9 million to prepare for the first clinical trials evaluating the psychedelic compound ibogaine for post-traumatic stress disorder (PTSD). Health Secretary Robert F. Kennedy Jr. announced that the funding is intended to establish the necessary foundation for manufacturing, dosing, and designing clinical evaluations, rather than funding direct patient research.
Derived from a West African shrub, ibogaine is currently illegal under federal law and classified alongside substances like LSD. While it can cause intense hallucinations, nausea, and severe heart rhythm issues, advocates and veterans groups argue it shows promise for treating PTSD, major depression, and opioid dependence.
To accelerate the process, federal officials plan to utilize data and treatment guidelines from Beond Inc., a Texas-based company that has treated over 3,000 individuals with ibogaine in Mexico. Veterans Affairs Secretary Doug Collins emphasized that the collaborative effort will prioritize safety and high-quality research to address the urgent needs of veterans.
Entities
Beond Inc. · Department of Health and Human Services · Doug Collins · Robert F. Kennedy Jr. · United States